GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PetMed Express Inc (NAS:PETS) » Definitions » ROE %
中文

PetMed Express (PetMed Express) ROE %

: -7.59% (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. PetMed Express's annualized net income for the quarter that ended in Dec. 2023 was $-8.1 Mil. PetMed Express's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $106.9 Mil. Therefore, PetMed Express's annualized ROE % for the quarter that ended in Dec. 2023 was -7.59%.

The historical rank and industry rank for PetMed Express's ROE % or its related term are showing as below:

PETS' s ROE % Range Over the Past 10 Years
Min: -2.78   Med: 24.95   Max: 35.66
Current: -2.78

During the past 13 years, PetMed Express's highest ROE % was 35.66%. The lowest was -2.78%. And the median was 24.95%.

PETS's ROE % is ranked worse than
65.85% of 609 companies
in the Healthcare Providers & Services industry
Industry Median: 4.11 vs PETS: -2.78

PetMed Express ROE % Historical Data

The historical data trend for PetMed Express's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetMed Express Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.14 19.53 17.63 14.14 4.40

PetMed Express Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.71 -3.11 -0.24 -7.59

Competitive Comparison

For the Pharmaceutical Retailers subindustry, PetMed Express's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetMed Express ROE % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, PetMed Express's ROE % distribution charts can be found below:

* The bar in red indicates where PetMed Express's ROE % falls into.



PetMed Express ROE % Calculation

PetMed Express's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=5.14/( (123.45+109.966)/ 2 )
=5.14/116.708
=4.40 %

PetMed Express's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-8.108/( (113.671+100.06)/ 2 )
=-8.108/106.8655
=-7.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


PetMed Express  (NAS:PETS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-8.108/106.8655
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.108 / 261.268)*(261.268 / 166.3105)*(166.3105 / 106.8655)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3.1 %*1.571*1.5563
=ROA %*Equity Multiplier
=-4.87 %*1.5563
=-7.59 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-8.108/106.8655
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-8.108 / -10.58) * (-10.58 / -12.296) * (-12.296 / 261.268) * (261.268 / 166.3105) * (166.3105 / 106.8655)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7664 * 0.8604 * -4.71 % * 1.571 * 1.5563
=-7.59 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


PetMed Express ROE % Related Terms

Thank you for viewing the detailed overview of PetMed Express's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


PetMed Express (PetMed Express) Business Description

Traded in Other Exchanges
Address
420 South Congress Avenue, Suite 100, Delray Beach, FL, USA, 33445
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies primarily to retail consumers.
Executives
Gian Fulgoni director
Christine Chambers officer: CFO 1501 1ST AVENUE SOUTH, STE. 600, SEATTLE WA 98134
Mathew N Hulett director, officer: CEO & President 1621 NORTH KENT STREET, SUITE 1200, ARLINGTON VA 22209
Campbell Leslie C.g. director C/O COUPA SOFTWARE INC., 1855 S. GRANT STREET, SAN MATEO CA 94402
Diana G Purcel director C/O FAMOUS DVES OF AMERICA INC, 8091 WALLACE ROAD, EDEN PRAIRIE MN 55344
Moseley Mark Bradley Jr other: Chief Technology Info Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Daniel Job Pingree other: Chief Marketing Officer 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Sandra Yvette Campos director 4900 E DUBLIN GRANVILLE RD, COLUMBUS OH 43081
Jacqueline Paula Smith other: Vice President of People 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Carolyn Carden other: VP of Product 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Peter Cobb director DSW, INC., 810 DSW DRIVE, COLUMBUS OH 43219
Jodi Watson director 420 SOUTH CONGRESS AVE., DELRAY BEACH FL 33445
Frank J Formica director 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069
Bruce S Rosenbloom officer: Chief Financial Officer 6401 CONGRESS AVENUE, SUITE 250, BOCA RATON FL 33487
Menderes Akdag director, officer: Chief Executive Officer 1441 S.W. 29TH AVENUE, POMPANO BEACH FL 33069